Intravenous Ibuprofen Market by Type, Product, Application, End User, and Region - Global Opportunity Analysis and Industry Forecast, Vendor Landscape, Market Growth, Trends & Forecast 2019 – 2025

According to a new market research report published by Apsters Research “Intravenous Ibuprofen Market by Indication, Age Group, End User, and Region - Global Opportunity Analysis and Industry Forecast, 2019 – 2025”, the global intravenous ibuprofen market is expected to reach USD xxx million by 2025 from USD xxx million in 2018, at a CAGR of xx% during the forecast period.

The research study focuses on the global intravenous ibuprofen market covering in-depth description, competitive scenario, product offerings of key vendors and business strategy adopted by competitors along with their SWOT analysis, revenue, sales and Porter's Five Forces Analysis.

Browse the full report at :

Research studies to evaluate applications of intravenous ibuprofen is providing growth opportunities to the key players

In order to develop the intravenous ibuprofen market, number of clinical studies were conducted to compare the efficacy of IV ibuprofen over IV ketorolac. These studies also focused on evaluating and finalize on the intravenous dose and infusion levels compared to the oral route of administration. In May 2018 a study was published studying the efficacy of IV ibuprofen in patients with post-procedural pain and nausea associated with uterine fibroid embolization (UFE). This and many such studies proved its efficacy as an intravenous non-steroidal anti-inflammatory agent and now, the upcoming studies are focused towards assessment of analgesic and antipyretic effect of intravenous ibuprofen in a surgical setting. Moreover, combination products are also being developed and launched to improve the effect and surge the efficacy of the drug.

Paradigm shift from opioids to non-opioid drugs is expected to drive the growth of this market

Globally, the demand for intravenous ibuprofen has significantly increased because of the side effects of opioids, such as allergic reactions, sedation, respiratory depression, and gastrointestinal events. Thus, paradigm shift from opioids to non-opioid drugs is the primary factor driving the growth of intravenous ibuprofen market. Additionally, advantages associated with intravenous ibuprofen, such as rapid result and targeted drug delivery, have also resulted in the growth of intravenous ibuprofen market globally. Furthermore, increasing focus towards post-operative care, approval for application of IV ibuprofen in paediatric patients, growing incidences and prevalence of chronic diseases such as cardiac ailments, and cancer, along with other medical conditions such as dental ailments, orthopaedic conditions, trauma and many other conditions inducing pain and inflammation are also driving the adoption of intravenous ibuprofen. However, regulatory barriers in the process of product approval, and side effects associated with the drug are likely to hamper the growth of this market during the forecast period.

The key segments of the intravenous ibuprofen market report:

The intravenous ibuprofen market is segmented on the basis of indication, age group, end user and geography. On the basis of indication, the market is segmented into pain and inflammation, fever, others. The age group segment is divided into pediatric and adults. the end user segment covers the market for hospitals and clinics, ambulatory surgery centers and specialty centers.

Enquire for detailed ToC and Sample Pages at -

North America to dominate the global Intravenous ibuprofen market in 2019

Geographic breakdown and deep analysis of each of the segments mentioned above is included for North America, Europe, Asia-Pacific, and Rest of the World. North America is expected to dominate the market by holding maximum market share of the global intravenous ibuprofen market. However, Asia-Pacific is expected to experience a fastest growth during the forecast period. Huge customer base, low manufacturing cost and growing number of product approvals are largely contributing to the growth of intravenous ibuprofen market in Asia-Pacific region. Moreover, increasing focus of key players towards expanding its business in this region also fuels the growth of this market.

Research and development activities and product launches enable the key players to enhance their market presence in the intravenous ibuprofen market

Providing quality products and gaining competitive market share is the major focus of the players operating in this market. Numerous players are focusing on research and development and product launches as their primary growth strategy. For instance, in 2018 AFT Pharmaceuticals has developed Maxigesic intravenous formulation, a combination of paracetamol and ibuprofen, for infusion. The company signed a licensing agreement with Kyongbo Pharmaceutical Co., Ltd to commercialize its product in South Korea. Such activities enable the companies to enhance their geographic presence, maintain market position, and gain market share in this competitive industry.

Some of the major companies profiled in the report include Cumberland Pharmaceuticals Inc., Alveda Pharmaceuticals, Inc., CSL Limited, Laboratorios Valmorca, C.A., Sandor Medicaids Pvt Ltd., PT. Soho Industri Pharmasi, Grifols S.A., Harbin Gloria Pharmaceuticals Co., Ltd., Al Nabeel International Ltd. and Germin MED. 

Recent Press Release